Abstract:Osteoporotic fractures, especially in elderly people, represent a health concern as they are associated with increased morbidity and mortality together with an increased economic burden for the society. During the past 20 years a great effort has been done in order to reduce the risk of fracture and many drugs are now available for this purpose, but osteoporosis is still regarded as an inevitable consequences of the aging process. Osteoporotic fractures occur most frequently in the spine and hip and with lower frequency in the wrist, pelvis, and upper arm. They are associated with significant morbidity and those of the hip and spine are also associated with excess mortality. The correct diagnosis and the adequate treatment of osteoporosis can reduce fracture risk. Together with well known anti-resorptive agents (like bisphosphonates, oestrogen and selective oestrogen receptor modulators) in the past few years anabolic therapy with parathyroid hormone (PTH) has become available for the treatment of severe osteoporosis. Human recombinant intact parathyroid hormone (PTH 1-84) and human recombinant PTH peptide 1-34 (Teriparatide) belong to this group of agents.This paper will review PTH actions together with the anabolic effect of PTH 1-84 both in reducing fracture risk and in promoting fracture healing. Although in primary hyperparathyroidism bone catabolism prevails on bone anabolism, PTH remains a potent stimulator of osteoblasts and its anabolic properties can be seen when it is given at a low dosage and intermittently. Intermittent PTH can stimulate bone formation to a greater extent and earlier than bone resorption, thus creating the so called "anabolic window".The TOP study demonstrated that PTH 1-84 is able to reduce the risk of a new fracture in patients with prevalent vertebral fractures, but the same effect was also seen on the incidence of the first fracture in women without fractures at baseline. Moreover PTH produced a continuous increase of bone mineral density, particularly in the cancellous bone. A positive effect of PTH has been described also on fracture healing, consisting both by a shortened time for fracture repair and by an improving of all the parameters of callus formation and development. Although most of the evidence has been obtained in animals some recent studies in humans confirmed, at least in part, these findings. In elderly patients with osteoporosis and fractures PTH treatment may reduce the healing time, improve clinical outcomes and reduce the time of immobilization together with the risk of complications.

Parathyroid hormone and its related peptides in bone metabolism

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis

PTH and the Regulation of Mesenchymal Cells within the Bone Marrow Niche

Intermittently Administered Parathyroid Hormone [1–34] Promotes Tendon-Bone Healing in a Rat Model

Parathyroid hormone related peptides affect diabetic osteoporotic fracture

Method of Parathyroid Hormone Acting on Bone Metabolism--related Genes Expression of Old Rats' Bone Marrow Cells

A Recombinant Parathyroid Hormone‐Related Peptide Locally Applied in Osteoporotic Bone Defect

A parathyroid hormone related supramolecular peptide for multi-functionalized osteoregeneration

PTHG2 Reduces Bone Loss in Ovariectomized Mice by Directing Bone Marrow Mesenchymal Stem Cell Fate

Parathyroid Hormone (PTH) Promotes ADSC Osteogenesis by Regulating SIK2 and Wnt4.

Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model.

Role of fibroblast growth factor 2 and wnt signaling in anabolic effects of parathyroid hormone on bone formation

PTH[1-34] Improves the Effects of Core Decompression in Early-Stage Steroid-Associated Osteonecrosis Model by Enhancing Bone Repair and Revascularization

Enhancing Bone Regeneration and Osseointegration using rhPTH(1-34) and Dimeric R25CPTH(1-34) in an Osteoporotic Beagle Model

Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations

Short carboxyl terminal parathyroid hormone peptides modulate human parathyroid hormone signaling in mouse osteoblasts

[Effect of signal-selective parathyroid hormone analogue peptide on expressions of Wnt signaling factors]

Molecular Mechanisms of Rhpth(1-34) Influence on Osteoporosis in Ovariectomized Rats

Pharmacological Effects of a Recombinant Hpth(1-34) Derived Peptide on Ovariectomized Rats.

Parathyroid Hormone and Bone Mineral Density: a Mendelian Randomization Study.